bioTheranostics Announces Update To Its bioT3 Metastatic Cancer Solution

SAN DIEGO--(BUSINESS WIRE)--bioTheranostics, Inc., today announced an important update to its bioT3 Metastatic Cancer Solution, a genomic testing platform that provides personalized diagnostic information and therapeutic guidance for metastatic cancer patients across the continuum of care.

The bioT3 suite of tests is a unique approach to metastatic cancer that combines the most validated gene expression panel to help achieve an accurate diagnosis, with a practice-oriented multiplatform solution that identifies the most relevant tumor-specific biomarkers to help guide treatment decisions. The approach provides information for patients with both clear and unclear diagnosis. The bioT3 Metastatic Cancer Solution includes:

Help employers find you! Check out all the jobs and post your resume.